Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS
about
CX3CL1 is up-regulated in the rat hippocampus during memory-associated synaptic plasticityCNS immune privilege: hiding in plain sight.CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin.Fractalkine/CX3CL1 enhances GABA synaptic activity at serotonin neurons in the rat dorsal raphe nucleusAnalysis of the Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Traumatic Brain and Spinal Cord Injury: Insight into Recent Advances in Actions of Neurochemokine Agents.Effects of acoustic trauma on the auditory system of the rat: The role of microgliaCC chemokine receptor 2 is protective against noise-induced hair cell death: studies in CX3CR1(+/GFP) mice.Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.The chemokine fractalkine can activate integrins without CX3CR1 through direct binding to a ligand-binding site distinct from the classical RGD-binding site.Interactions between chemokines: regulation of fractalkine/CX3CL1 homeostasis by SDF/CXCL12 in cortical neurons.Protracted downregulation of CX3CR1 on microglia of aged mice after lipopolysaccharide challengeRole of fractalkine/CX3CR1 interaction in light-induced photoreceptor degeneration through regulating retinal microglial activation and migrationFractalkine receptor (CX3CR1) deficiency sensitizes mice to the behavioral changes induced by lipopolysaccharideInteractions between chemokine and mu-opioid receptors: anatomical findings and electrophysiological studies in the rat periaqueductal grey.Expression of fractalkine and fractalkine receptor in urinary bladder after cyclophosphamide (CYP)-induced cystitis.Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis.Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.Microglial Cx3cr1 knockout reduces prion disease incubation time in miceInvolvement of CX3CL1/CX3CR1 signaling in spinal long term potentiation.Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease.Neuronal Cx3cr1 Deficiency Protects against Amyloid β-Induced Neurotoxicity.Fractalkine/CX3CL1 protects striatal neurons from synergistic morphine and HIV-1 Tat-induced dendritic losses and deathMicroglia in the developing brain: a potential target with lifetime effects.In vivo structure/function and expression analysis of the CX3C chemokine fractalkineCX3C chemokine receptor 1 deficiency modulates microglia morphology but does not affect lesion size and short-term deficits after experimental stroke.Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance PIndoleamine 2,3-dioxygenase inhibition attenuates lipopolysaccharide induced persistent microglial activation and depressive-like complications in fractalkine receptor (CX(3)CR1)-deficient mice.Fractalkine Attenuates Microglial Cell Activation Induced by Prenatal Stress.Neuronal chemokines: versatile messengers in central nervous system cell interaction.The effects of CX3CR1 deficiency and irradiation on the homing of monocyte-derived cell populations in the mouse eye.Microglia during development and aging.Neuronal influence behind the central nervous system regulation of the immune cells.Retinal vascular repair and neovascularization are not dependent on CX3CR1 signaling in a model of ischemic retinopathyKnockout of fractalkine receptor Cx3cr1 does not alter disease or microglial activation in prion-infected miceWIN55,212-2 inhibits production of CX3CL1 by human astrocytes: involvement of p38 MAP kinaseInactivation of astroglial NF-kappa B promotes survival of retinal neurons following ischemic injury.Neuron-glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage.Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis.Microglial control of neuronal activity.Factors regulating microglia activation
P2860
Q21129473-646A5718-EED0-4CAE-AADD-7EFED1FF2B71Q24642697-8E3C4D6B-DEBA-422D-86C2-F12540B1136EQ24814510-DA59964C-C831-4E57-90E1-73EA94B65946Q28570501-9F4E91D6-9186-47C3-9B6B-28AE4387A7F9Q30360306-E17459D5-5AAC-45E3-9CC5-24D782F03E95Q30374708-B4DC406B-EC0D-48D1-9E56-E20FACD2CE96Q30492539-E82E7F16-CA23-4400-AEC5-F839AFFC7A1EQ30578913-613BD280-FBC7-4BE7-A6B5-45770BF46A9EQ31160040-D8F1B38C-78E2-49A5-AC49-BA261A95812DQ33796131-C41DD9EE-1975-4B7F-8C2E-F159F3947888Q34127089-A0489039-5A0A-41DF-83ED-DA33ED47582BQ34247267-09AED1EC-3985-4CBF-976E-AF5EE32A428CQ34478106-9AB044C0-E356-44FE-B7DF-0D2514DF6341Q34511063-259022E0-2FD2-482B-8695-C39EBD1B8FB8Q34666901-C71FD05D-13C2-43E8-96A5-6C017A71A25EQ34828549-702701E2-F2BF-4E98-A6C7-185CC91AB8C8Q35122783-66DDCE6D-FBFE-40CF-B26C-78BF3A981C98Q35127326-E78B14A4-90BA-486F-81F7-185FC2F11BF0Q35576920-BB12B158-D6AB-4B6A-BE2C-0399095AD71BQ35609611-F99D7EBE-81B5-4A35-851B-EECE4A3CC2C5Q35650827-E735DA7B-37D5-4569-ADA3-B70EED5890C8Q35779848-83A3F639-D230-42A4-93D7-C8F6D7E8EDF1Q35823222-C7741F68-AF6E-4BCD-9D50-C2F6123FEB19Q35865080-0F611442-3D3A-4D54-A1C8-375B78F1F18DQ36243228-DC61E5D0-2149-4ACB-9B00-FFE77C19DD82Q36464353-11DA8A76-3C43-4801-8BC7-2E3CD8089362Q36561722-B0DEF18A-18B2-47A5-8CAF-9DAE3A726496Q36889750-C7E2A73A-68B2-4C9B-97C8-BB1D2E6AD44AQ36977783-ED3E3C17-BE54-4FCA-AB6C-48629AF09DD5Q36981052-F817BEEA-D3FD-4D97-A3EC-58E2CE931CA6Q37080038-498D8B6E-F837-40D8-A852-953933989A03Q37136971-E3246EA6-C9E9-4656-989B-DB31FD631E83Q37194989-DFBB4A05-0E04-4AC7-A5B7-0507FB296997Q37296027-2959A56C-816B-47F6-892F-D2DB55A4EE89Q37312658-471D475F-7808-49A7-8F8B-9F8393D5FA08Q37423557-A9636D80-6B82-4E92-9EE0-99367CC7F73FQ37424844-8F70A814-0805-40A1-9E07-14993E9A2C5AQ37702072-A5ABA8A9-735A-438D-9DA5-5E40F063C80CQ38094700-3C095AA3-D375-4BD4-B6D6-09920EB063AAQ38102983-278F892D-C6C9-4A4F-A4F9-657269B4225A
P2860
Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS
description
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2002
@ast
im März 2002 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2002/03/15)
@sk
vědecký článek publikovaný v roce 2002
@cs
wetenschappelijk artikel (gepubliceerd op 2002/03/15)
@nl
наукова стаття, опублікована в березні 2002
@uk
مقالة علمية (نشرت في 15-3-2002)
@ar
name
Expression of fractalkine (CX3 ...... inflammation in the rodent CNS
@ast
Expression of fractalkine (CX3 ...... inflammation in the rodent CNS
@en
Expression of fractalkine (CX3 ...... inflammation in the rodent CNS
@nl
type
label
Expression of fractalkine (CX3 ...... inflammation in the rodent CNS
@ast
Expression of fractalkine (CX3 ...... inflammation in the rodent CNS
@en
Expression of fractalkine (CX3 ...... inflammation in the rodent CNS
@nl
prefLabel
Expression of fractalkine (CX3 ...... inflammation in the rodent CNS
@ast
Expression of fractalkine (CX3 ...... inflammation in the rodent CNS
@en
Expression of fractalkine (CX3 ...... inflammation in the rodent CNS
@nl
P2093
P3181
P356
P1433
P1476
Expression of fractalkine (CX3 ...... inflammation in the rodent CNS
@en
P2093
Michelle Sandra Botham
Paula Marie Hughes
Stefan Frentzel
Victor Hugh Perry
P304
P3181
P356
10.1002/GLIA.10037.ABS
P577
2002-03-15T00:00:00Z